Novartis gets positive CHMP opinion for Cosentyx in adults with hidradenitis suppurativa Ruchika Sharma30 April 2023 10:00 AM ISTCosentyx is the first and only fully human biologic that directly inhibits interleukin-17A, an important cytokine involved in the inflammation of...
Switching to Risankizumab cost-effective and safe for psoriasis patients in case of secukinumab failure Aditi18 April 2023 8:00 PM ISTA research letter published in Experimental Dermatology written by Chang-Yu Hsieh from the Department of Dermatology, National Taiwan University...
Secukinumab effectively reduces symptoms and signs of hidradenitis suppurativa Jacinthlyn Sylvia5 March 2023 8:00 PM ISTSecukinumab, when administered every two weeks, was clinically successful at reducing the symptoms and signs of hidradenitis suppurativa while...
Secukinumab Dose Tapering ensures increased effectiveness of plaque psoriasis treatment Dr. Kamal Kant Kohli21 Oct 2022 7:30 PM ISTCHINA: According to a research study published in the journal Dermatologic Therapy, tapering off secukinumab dosages for individuals with plaque...
Secukinumab effective for treating pityriasis rubra pilaris: Study Jacinthlyn Sylvia19 Sept 2022 8:00 PM ISTUSA: Secukinumab is a good therapy with favorable outcomes for pityriasis rubra pilaris (PRP) and deserves more research, suggests an article...
Cosentyx shows clinically meaningful symptom improvements in patients with painful skin condition in pivotal Phase III trials: Novartis Ruchika Sharma12 Sept 2022 3:00 PM ISTHidradenitis Suppurativa is a chronic, inflammatory, debilitating skin condition with systemic comorbidities that has a profoundly negative effect on...
Novartis Cosentyx gets positive CHMP opinion for expanded use in childhood arthritic conditions Ruchika Sharma23 May 2022 10:00 AM ISTBasel: Novartis has announced the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a...
Novartis gets CDSCO panel okay for phase 3 trial of Secukimunab Dr. Divya Colin23 Feb 2022 3:10 PM ISTNew Delhi: The pharmaceutical major, Novartis, has got a go-ahead from the Subject Expert Committee (SEC) of the Central Drugs Standard Control...
First case of Granuloma annulare after ixekizumab administration reported Dr Manoj Kumar Nayak10 Dec 2021 9:00 AM ISTGranuloma annulare post ixekizumab administration- 1 case report Psoriasis is a complex immune mediated disease influenced by multiple genetic...
Intramatricial injection of anti-IL-17A Ab efficacious in nail psoriasis : CED study Dr Manoj Kumar Nayak25 Sept 2021 9:00 AM ISTIntramatricial injection of anti-IL-17A Ab efficacious in nail psoriasis : CED study1 Nail involvement is a common feature of psoriasis commonly...
Novartis pediatric psoriasis treatment Cosentyx approved in China Ruchika Sharma18 Aug 2021 3:46 PM ISTBasel: Novartis has recently announced that the China National Medical Products Administration (NMPA) has further approved Cosentyx (secukinumab) for...
Secukinumab has low malignancy risk in patients of Psoriasis and psoriatic arthritis: Study MD Bureau2 July 2021 9:00 AM ISTPsoriasis is an auto-immune disease that causes red, scaly patches to occur on the skin. It is a chronic disease and is caused, at least in part, by...
